Evidence map›Paper›PMID 41965730›Full record

ArticleBlood cancer journal2026

CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia.

Saubia Fathima, Lior Rokach, Muhammad Yousuf, Priyansh Faldu, Ali Alsugair, Clifford Csizmar, Merry Nakhleh, Abhishek A Mangaonkar, Animesh Pardanani, Luca Lanino and 10 more

Abstract read
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Saubia FathimaDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-9979-7923
Lior RokachDepartment of Software & Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel.ORCID 0000-0002-6956-3341
Muhammad YousufDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
Priyansh FalduDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
Ali AlsugairDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
Clifford CsizmarDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-1221-8854
Merry NakhlehDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
Abhishek A MangaonkarDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-2458-9887
Animesh PardananiDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
Luca LaninoDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0003-2404-8829
Alessia CampagnaDepartment of Hematology Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Giulia MaggioniDepartment of Hematology Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Noushin FarnoudCenter for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Raajit RampalCenter for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-0355-6368
Kaaren K ReichardDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5439-0778
Rong HeDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-6116-8163
Naseema GangatDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-9104-6172
Mrinal M PatnaikDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-6998-662X
Matteo G Della PortaDepartment of Hematology Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Ayalew TefferiDivisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA. tefferi.ayalew@mayo.edu.ORCID 0000-0003-4605-3821

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Contemporary risk models in chronic myelomonocytic leukemia (CMML) focus on the prognostic relevance of individual rather than concurrent mutations. In the current study of 605 Mayo Clinic patients with CMML, we applied machine-learning algorithms in order to examine the influence of cooperative mutational interactions on blast transformation (BT). A hierarchical clustering algorithm was developed and tailored for patient stratification using survival outcomes and co-occurrence of genomic alterations. Five molecular clusters were identified with 3-year blast BT rates ranging from 0% to 100% (AUC at 3 years 0.78). A subsequent Cox regression analysis confirmed independent detrimental impact of specific mutations or their combinations including NPM1 (HR 26.7; p < 0.01), "NRAS + SETBP1" (HR 12.6; p < 0.01), "ASXL1 + BCOR" (HR 8.4; p < 0.01), "ASXL1 + RUNX1" (HR 2.2, p < 0.01), JAK2 (HR 2.1; p < 0.01), and "ASXL1 + TET2" (HR 1.7; p = 0.02) while "PHF6+wild-type ASXL1" (HR 5.61e-10; p < 0.01) had a favorable impact. Furthermore, compared to NPM1 wild-type cases, NPM1-mutated patients were less likely to have co-occurring mutations involving ASXL1 (0% vs. 43%, p < 0.01), RUNX1 (0% vs. 17%, p = 0.02), and SRSF2 (7% vs. 39%, p < 0.01) and were more likely DNMT3A (71% vs. 7%, p < 0.01). The prognostic relevance of "NRAS + SETBP1", "ASXL1 + RUNX1", NPM1 and BCOR was validated in an external cohort from Italy (N = 501). Taken together, these observations highlight i) the possibility of prognostic interaction of mutations in CMML that should be considered in the development of future risk models and ii) the distinct genotypic and prognostic characteristics of NPM1-mutated CMML.

Indexed as

Blast CrisisLeukemia, Myelomonocytic, ChronicMachine LearningMutationClustering AlgorithmsFemaleHumansMaleNucleophosminPrognosisNPM1 protein, humanNucleophosmin

Identifiers

PMID41965730
PMCPMC13181037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.